Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

Clinical Cancer Research

Volumn 11, Issue 15, 2005, Pages 5472-5480

  Clark, Jeffrey W ^a   Eder, Joseph P ^a   Ryan, David ^a   Lathia, Chetan ^b   Lenz, Heinz Josef ^c  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b BAYER CORPORATION   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE INHIBITOR; RAF PROTEIN; SORAFENIB; VASCULOTROPIN INHIBITOR;

ABDOMINAL CRAMP; ADULT; AGED; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER INHIBITION; CANCER MORTALITY; CANCER RESISTANCE; CANCER STAGING; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONSTIPATION; DEHYDRATION; DESQUAMATION; DIARRHEA; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EMBOLISM; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPONATREMIA; HYPOXIA; INFECTION; LIVER TOXICITY; LUNG TOXICITY; MALE; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PAIN; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PLEURISY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PRURITUS; RASH; SIGNAL TRANSDUCTION; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; THROMBOSIS; TUMOR GROWTH; URETER OBSTRUCTION; UROGENITAL TRACT DISEASE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BENZENESULFONATES; BIOPSY; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RAF KINASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 23044510046     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2658     Document Type: Article

References (18)

1. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 2002;25:511-8.
2. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
3. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 2002;62:3729-35.
4. Doanes AM, Hegland DD, Sethi R, Kovesdi I, Bruder JT, Finkel T. VEGF stimulates MARK through a pathway that is unique for receptor tyrosine kinases. Biochem Biophys Res Commun 1999;255:545-8.
5. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2002;103:211-25.
6. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
7. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 2001;8:219-25.
8. Wilhelm S, Housley T, Kennure N, et al. BAY 43-9006, a novel Raf-1 kinase inhibitor (RKI) blocks the Raf/MEK/ERK pathway in tumor cells [Abstract]. Proc Am Assoc Cancer Res 2001;42:923.
9. Wilhelm S, Housley T, Rong H, et al. The novel Raf inhibitor BAY 43-9006 blocks signaling and proliferation in BRAF mutant and wildtype melanoma and colorectal tumor cell lines [Abstract]. Proc Am Assoc Cancer Res 2003;44:106609.
10. Lee JT, McCubrey JA. BAY-43-9006 Bayer/Onyx. Curr Opin Investig Drugs 2003;4:757-63.
11. Strumberg D, Awada A, Piccart P, et al. Final report of the multiple single agent phase I clinical trials of the novel Raf kinase inhibitor BAY 43-9006 in patients with refractory solid tumors [Abstract]. Proc Am Soc Clin Oncol 2003;22:203.
12. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact of radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:13-47.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16
14. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
15. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
16. Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 1997;76:930-4.
17. Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995;55:4182-7.
18. Ljungberg B, Jacobsen J, Haggstrom-Rudolfssson S, Rasmuson T, Lindh G, Grankvist K. Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma. Urol Res 2003;31:335-40.